$VNDA
Vanda Pharmaceuticals Inc.

2021 Q4 Form 10-K Financial Statement

#000162828022003629 Filed on February 24, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $68.02M $268.7M $67.65M
YoY Change 0.54% 8.27% 11.03%
Cost Of Revenue $6.236M $25.63M $6.410M
YoY Change -2.71% 9.53% 2.89%
Gross Profit $61.78M $243.1M $60.87M
YoY Change 1.5% 8.12% 12.03%
Gross Profit Margin 90.83% 90.46% 89.98%
Selling, General & Admin $33.45M $124.0M $35.57M
YoY Change -5.97% -11.72% -3.92%
% of Gross Profit 54.14% 51.04% 58.44%
Research & Development $985.0K $75.36M $13.15M
YoY Change -92.51% 35.6% 0.61%
% of Gross Profit 1.59% 31.01% 21.6%
Depreciation & Amortization $706.0K $1.400M $800.0K
YoY Change -11.75% 0.0% 0.0%
% of Gross Profit 1.14% 0.58% 1.31%
Operating Expenses $33.35M $199.4M $49.09M
YoY Change -32.07% 1.69% -2.72%
Operating Profit $28.44M $42.17M $10.45M
YoY Change 172.09% 54.8% 146.31%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$26.00K $199.0K $470.0K
YoY Change -105.53% -95.48% -70.06%
Pretax Income $8.610M $42.36M $10.92M
YoY Change -21.15% 33.83% 87.95%
Income Tax $1.532M $9.212M $2.730M
% Of Pretax Income 17.79% 21.74% 25.0%
Net Earnings $7.078M $33.15M $8.190M
YoY Change -13.58% 42.06% 94.26%
Net Earnings / Revenue 10.41% 12.34% 12.11%
Basic Earnings Per Share $0.60 $0.15
Diluted Earnings Per Share $123.7K $0.58 $0.15
COMMON SHARES
Basic Shares Outstanding 55.71M shares 55.55M shares 54.69M shares
Diluted Shares Outstanding 56.92M shares

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $432.8M $432.8M $367.7M
YoY Change 17.7% 17.71% 17.82%
Cash & Equivalents $52.07M $52.07M $61.03M
Short-Term Investments $380.7M $380.7M $306.7M
Other Short-Term Assets $12.00M $12.00M $10.10M
YoY Change 18.77% 18.77% -30.34%
Inventory $1.025M $1.025M $1.280M
Prepaid Expenses
Receivables $32.47M $32.47M $30.04M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $478.3M $478.3M $409.1M
YoY Change 16.9% 16.92% 15.53%
LONG-TERM ASSETS
Property, Plant & Equipment $3.113M $12.39M $4.136M
YoY Change -24.73% -15.17% 7.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $83.03M $83.03M $88.20M
YoY Change -5.87% -5.87% -3.61%
Total Long-Term Assets $115.5M $115.5M $124.3M
YoY Change -7.1% -7.16% -4.09%
TOTAL ASSETS
Total Short-Term Assets $478.3M $478.3M $409.1M
Total Long-Term Assets $115.5M $115.5M $124.3M
Total Assets $593.8M $593.8M $533.5M
YoY Change 11.31% 11.3% 10.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.873M $5.873M $5.800M
YoY Change 1.26% 1.26% -1.69%
Accrued Expenses $68.55M $68.55M $59.80M
YoY Change 14.63% 14.63% 11.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $74.42M $74.42M $65.94M
YoY Change 12.87% 12.93% 10.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.390M $14.45M $2.757M
YoY Change 59.23% 1.01% 227.05%
Total Long-Term Liabilities $4.390M $14.45M $2.757M
YoY Change 59.23% 1.01% 227.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $74.42M $74.42M $65.94M
Total Long-Term Liabilities $4.390M $14.45M $2.757M
Total Liabilities $88.86M $88.86M $80.19M
YoY Change 10.82% 10.8% 10.15%
SHAREHOLDERS EQUITY
Retained Earnings -$164.2M -$197.3M
YoY Change -16.8% -10.58%
Common Stock $669.3M $650.4M
YoY Change 2.91% 3.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $504.9M $504.9M $453.3M
YoY Change
Total Liabilities & Shareholders Equity $593.8M $593.8M $533.5M
YoY Change 11.31% 11.3% 10.28%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income $7.078M $33.15M $8.190M
YoY Change -13.58% 42.06% 94.26%
Depreciation, Depletion And Amortization $706.0K $1.400M $800.0K
YoY Change -11.75% 0.0% 0.0%
Cash From Operating Activities $26.61M $64.21M $19.30M
YoY Change 37.86% 24.03% 98.97%
INVESTING ACTIVITIES
Capital Expenditures -$134.0K $552.0K -$1.000M
YoY Change -86.6% -69.25%
Acquisitions
YoY Change
Other Investing Activities -$25.86M -$76.14M -$15.70M
YoY Change 64.74% 91.8% 153.23%
Cash From Investing Activities -$26.00M -$76.70M -$16.70M
YoY Change 55.68% 84.81% 169.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.041M $3.550M 1.400M
YoY Change -25.64% -36.99% -36.36%
NET CHANGE
Cash From Operating Activities 26.61M $64.21M 19.30M
Cash From Investing Activities -26.00M -$76.70M -16.70M
Cash From Financing Activities 1.041M $3.550M 1.400M
Net Change In Cash 1.650M -$9.023M 4.000M
YoY Change -58.75% -156.52% -29.82%
FREE CASH FLOW
Cash From Operating Activities $26.61M $64.21M $19.30M
Capital Expenditures -$134.0K $552.0K -$1.000M
Free Cash Flow $26.74M $63.66M $20.30M
YoY Change 31.73% 27.37% 109.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001347178
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-34186
CY2021 dei Entity Registrant Name
EntityRegistrantName
VANDA PHARMACEUTICALS INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
03-0491827
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
2200 Pennsylvania Avenue NW
CY2021 dei City Area Code
CityAreaCode
202
CY2021 dei Local Phone Number
LocalPhoneNumber
734-3400
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300 E
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Washington
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
DC
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20037
CY2021 dei Auditor Name
AuditorName
PricewaterhouseCoopers LLP
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021 dei Trading Symbol
TradingSymbol
VNDA
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
false
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
1169300000 USD
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55906855 shares
CY2021 dei Auditor Firm
AuditorFirmId
238
CY2021 dei Auditor Location
AuditorLocation
Baltimore, Maryland
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52071000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61031000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
380742000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
306709000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32467000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
30036000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
1025000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
1280000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11996000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10089000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
478301000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
409145000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3113000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4136000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9272000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10459000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
20081000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
21559000 USD
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
74878000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
81516000 USD
CY2021Q4 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
8147000 USD
CY2020Q4 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
6641000 USD
CY2021Q4 us-gaap Assets
Assets
593792000 USD
CY2020Q4 us-gaap Assets
Assets
533456000 USD
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
34438000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
31509000 USD
CY2021Q4 vnda Product Revenue Allowances Current
ProductRevenueAllowancesCurrent
39981000 USD
CY2020Q4 vnda Product Revenue Allowances Current
ProductRevenueAllowancesCurrent
34427000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
74419000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
65936000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10055000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11497000 USD
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4390000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2757000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
88864000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
80190000 USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55900855 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55900855 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54865092 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54865092 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
56000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
55000 USD
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
669223000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
650300000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-175000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197328000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
239000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-164176000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
504928000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
453266000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
593792000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
533456000 USD
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
268682000 USD
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
248168000 USD
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
227188000 USD
CY2021 us-gaap Revenues
Revenues
268682000 USD
CY2020 us-gaap Revenues
Revenues
248168000 USD
CY2019 us-gaap Revenues
Revenues
227188000 USD
CY2021 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
25629000 USD
CY2020 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
23364000 USD
CY2019 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
24488000 USD
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
75363000 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
55577000 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48649000 USD
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
124047000 USD
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
140510000 USD
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
129736000 USD
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1478000 USD
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1478000 USD
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1505000 USD
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
226517000 USD
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
220929000 USD
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
204378000 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
42165000 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
27239000 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
22810000 USD
CY2021 us-gaap Other Income
OtherIncome
199000 USD
CY2020 us-gaap Other Income
OtherIncome
4416000 USD
CY2019 us-gaap Other Income
OtherIncome
6218000 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
42364000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
31655000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
29028000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9212000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8318000 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-86525000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
33152000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
23337000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
115553000 USD
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.60
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.43
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.17
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.58
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.42
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.11
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55548122 shares
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54427683 shares
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53137562 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56921836 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55190802 shares
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54847060 shares
CY2021 us-gaap Net Income Loss
NetIncomeLoss
33152000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
23337000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
115553000 USD
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-49000 USD
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
68000 USD
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
6000 USD
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-472000 USD
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-102000 USD
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
313000 USD
CY2021 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-107000 USD
CY2020 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-24000 USD
CY2019 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
71000 USD
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-414000 USD
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-10000 USD
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
248000 USD
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
32738000 USD
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
23327000 USD
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
115801000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
275422000 USD
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6264000 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13458000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
115553000 USD
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
248000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
410945000 USD
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5634000 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13360000 USD
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15374000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
33152000 USD
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-414000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
33152000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
23337000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
504928000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
23337000 USD
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-10000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
453266000 USD
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3550000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
115553000 USD
CY2021 us-gaap Depreciation
Depreciation
1363000 USD
CY2020 us-gaap Depreciation
Depreciation
1386000 USD
CY2019 us-gaap Depreciation
Depreciation
1387000 USD
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
15374000 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
13360000 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
13458000 USD
CY2021 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-1649000 USD
CY2020 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-179000 USD
CY2019 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
3099000 USD
CY2021 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
12000 USD
CY2020 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
229000 USD
CY2019 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 USD
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1478000 USD
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1478000 USD
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1505000 USD
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
6745000 USD
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
6189000 USD
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-87767000 USD
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1728000 USD
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1758000 USD
CY2019 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1785000 USD
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2469000 USD
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3767000 USD
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2342000 USD
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2233000 USD
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2876000 USD
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1247000 USD
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4068000 USD
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2764000 USD
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
722000 USD
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3040000 USD
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3759000 USD
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3508000 USD
CY2021 vnda Increase Decrease Product Revenue Allowances
IncreaseDecreaseProductRevenueAllowances
5646000 USD
CY2020 vnda Increase Decrease Product Revenue Allowances
IncreaseDecreaseProductRevenueAllowances
3133000 USD
CY2019 vnda Increase Decrease Product Revenue Allowances
IncreaseDecreaseProductRevenueAllowances
761000 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
64214000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
51775000 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
45947000 USD
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
552000 USD
CY2019 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
394517000 USD
CY2021 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
344317000 USD
CY2020 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
306918000 USD
CY2019 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
327227000 USD
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-76696000 USD
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1795000 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1019000 USD
CY2021 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
420461000 USD
CY2020 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
346622000 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41499000 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-68309000 USD
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3550000 USD
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5634000 USD
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6264000 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3550000 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5634000 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6264000 USD
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-91000 USD
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53000 USD
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1000 USD
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9023000 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15963000 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16099000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61613000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45650000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61749000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52590000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61613000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45650000 USD
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021 vnda Number Of Products In Portfolio
NumberOfProductsInPortfolio
2 product
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management’s evaluation could change. Actual results could differ from those estimates.</span></div>
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52071000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61031000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52590000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61613000 USD
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
268682000 USD
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
248168000 USD
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
227188000 USD
CY2021 vnda Percentage Of Responsibility For Patients Cost Of Branded Prescription Under Medicare Part D
PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD
0.70
CY2021 us-gaap Advertising Expense
AdvertisingExpense
6700000 USD
CY2020 us-gaap Advertising Expense
AdvertisingExpense
12600000 USD
CY2019 us-gaap Advertising Expense
AdvertisingExpense
3200000 USD
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
381009000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
114000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
381000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
380742000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
306504000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
216000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
306709000 USD
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
380742000 USD
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
306709000 USD
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
66000 USD
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
995000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1214000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
1025000 USD
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
30000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
1280000 USD
CY2021Q4 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
2143000 USD
CY2020Q4 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
744000 USD
CY2021Q4 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
3934000 USD
CY2020Q4 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
4045000 USD
CY2021Q4 vnda Inventory Finished Goods Net Of Reserves Non Current
InventoryFinishedGoodsNetOfReservesNonCurrent
1150000 USD
CY2020Q4 vnda Inventory Finished Goods Net Of Reserves Non Current
InventoryFinishedGoodsNetOfReservesNonCurrent
302000 USD
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
7227000 USD
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
5091000 USD
CY2021Q4 vnda Inventory
Inventory
8252000 USD
CY2020Q4 vnda Inventory
Inventory
6371000 USD
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12490000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12164000 USD
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9377000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8028000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3113000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4136000 USD
CY2021 us-gaap Depreciation
Depreciation
1400000 USD
CY2019 us-gaap Depreciation
Depreciation
1400000 USD
CY2020 us-gaap Depreciation
Depreciation
1400000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9272000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10459000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2311000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2117000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10055000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11497000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
12366000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
13614000 USD
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y2M12D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y1M6D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.081
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.081
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
2300000 USD
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
2300000 USD
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
2300000 USD
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
400000 USD
CY2019 us-gaap Short Term Lease Cost
ShortTermLeaseCost
400000 USD
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
400000 USD
CY2021 vnda Operating Lease Non Lease Component Expense
OperatingLeaseNonLeaseComponentExpense
1400000 USD
CY2020 vnda Operating Lease Non Lease Component Expense
OperatingLeaseNonLeaseComponentExpense
1500000 USD
CY2019 vnda Operating Lease Non Lease Component Expense
OperatingLeaseNonLeaseComponentExpense
1400000 USD
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
2300000 USD
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
2600000 USD
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
2500000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2608000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2461000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2488000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2557000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2366000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
3258000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
15738000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3372000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
12366000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2311000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10055000 USD
CY2021Q4 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
10082000 USD
CY2020Q4 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
6173000 USD
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
8732000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5052000 USD
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6515000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10951000 USD
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5873000 USD
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5817000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2311000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2117000 USD
CY2021Q4 vnda Accrued Milestone Obligations Under License Agreements
AccruedMilestoneObligationsUnderLicenseAgreements
0 USD
CY2020Q4 vnda Accrued Milestone Obligations Under License Agreements
AccruedMilestoneObligationsUnderLicenseAgreements
350000 USD
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
925000 USD
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1049000 USD
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
34438000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
31509000 USD
CY2021 vnda Agreements For Clinical And Marketing Services Termination Notice Period
AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod
P90D
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
32000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
81000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-207000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
158000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-175000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
239000 USD
CY2021 vnda Share Based Compensation Option Awards Contractual Term
ShareBasedCompensationOptionAwardsContractualTerm
P10Y
CY2021 vnda Share Based Compensation Arrangementby Share Based Payment Annual Award Vesting Period Employeesand New Directors
ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors
P4Y
CY2021 vnda Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards
0.25
CY2021 vnda Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards
0.75
CY2021 vnda Sharebased Compensation Arrangementby Share Based Payment Award Options Vesting Period Number Of Equal Monthly Installments
SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments
36 installment
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.91
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.53
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.19
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4100000 USD
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2900000 USD
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2500000 USD
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3600000 USD
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5600000 USD
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6300000 USD
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15374000 USD
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13360000 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13458000 USD
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.46
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.51
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.58
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M23D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M12D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0075
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0114
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0226
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2021 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.06
CY2021 vnda Defined Contribution Plan Vesting Period
DefinedContributionPlanVestingPeriod
P4Y
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1000000 USD
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
900000 USD
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
800000 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
42221000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
31667000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
28794000 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
143000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-12000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
234000 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
42364000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
31655000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
29028000 USD
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2200000 USD
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2061000 USD
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1161000 USD
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
267000 USD
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
68000 USD
CY2019 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
81000 USD
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
6604000 USD
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
6076000 USD
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-85624000 USD
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
119000 USD
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
155000 USD
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-2127000 USD
CY2021 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
22000 USD
CY2020 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-42000 USD
CY2019 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-16000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9212000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8318000 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-86525000 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.023
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.026
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.018
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.001
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.054
CY2019 vnda Effective Income Tax Rate Reconciliation Uncertain Tax Positions Percent
EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent
0.263
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.035
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-3.576
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.065
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.109
CY2021 vnda Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug
EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug
-0.001
CY2020 vnda Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug
EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug
-0.013
CY2019 vnda Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug
EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug
0.171
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.026
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.017
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.027
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.002
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.002
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.005
CY2021 vnda Effective Income Tax Rate Reconciliation Uncertain Tax Positions Percent
EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent
0.040
CY2020 vnda Effective Income Tax Rate Reconciliation Uncertain Tax Positions Percent
EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent
0.047
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.018
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.051
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.012
CY2019 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.010
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.005
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.030
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.217
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.263
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-2.981
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
35509000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
43623000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
4846000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
4653000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1409000 USD
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
8223000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2429000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
1142000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
1169000 USD
CY2021Q4 vnda Deferred Tax Assets Tax Credit Carryforwards Research And Other
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
39975000 USD
CY2020Q4 vnda Deferred Tax Assets Tax Credit Carryforwards Research And Other
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
37737000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
3081000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
3279000 USD
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
85962000 USD
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
92890000 USD
CY2021Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1919000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1911000 USD
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
2140000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
2412000 USD
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
4059000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
4323000 USD
CY2021Q4 vnda Deferred Tax Assets Liabilities Before Valuation Allowance Net
DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet
81903000 USD
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1580000 USD
CY2020Q4 vnda Deferred Tax Assets Liabilities Before Valuation Allowance Net
DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet
88567000 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7025000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7051000 USD
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
74878000 USD
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
81516000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7051000 USD
CY2021 vnda Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
0 USD
CY2021 vnda Deferred Tax Assets Valuation Allowance Decrease
DeferredTaxAssetsValuationAllowanceDecrease
26000 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7025000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8155000 USD
CY2020 vnda Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
0 USD
CY2020 vnda Deferred Tax Assets Valuation Allowance Decrease
DeferredTaxAssetsValuationAllowanceDecrease
1104000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7051000 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
111950000 USD
CY2019 vnda Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
0 USD
CY2019 vnda Deferred Tax Assets Valuation Allowance Decrease
DeferredTaxAssetsValuationAllowanceDecrease
103795000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8155000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
15500000 USD
CY2021 vnda Operating Loss Carryforwards Beginning Expiration Year
OperatingLossCarryforwardsBeginningExpirationYear
2033
CY2021 vnda Research And Development Credit Beginning Expiration Year
ResearchAndDevelopmentCreditBeginningExpirationYear
2024
CY2021 vnda Orphan Drug Credit Beginning Expiration Year
OrphanDrugCreditBeginningExpirationYear
2030
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
8300000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11233000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9741000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
122000 USD
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
121000 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
12935000 USD
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54427683 shares
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53137562 shares
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1613000 USD
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1518000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11233000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9741000 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
12900000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
33152000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
23337000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
115553000 USD
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55548122 shares
CY2021 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1373714 shares
CY2020 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
763119 shares
CY2019 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1709498 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56921836 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55190802 shares
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54847060 shares
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.60
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.43
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.17
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.58
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.42
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.11
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2176944 shares
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3407409 shares
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1932024 shares

Files In Submission

Name View Source Status
0001628280-22-003629-index-headers.html Edgar Link pending
0001628280-22-003629-index.html Edgar Link pending
0001628280-22-003629.txt Edgar Link pending
0001628280-22-003629-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vnda-20211231.htm Edgar Link pending
vnda-20211231.xsd Edgar Link pending
vnda-20211231_cal.xml Edgar Link unprocessable
vnda-20211231_def.xml Edgar Link unprocessable
vnda-20211231_g1.gif Edgar Link pending
vnda-20211231_g2.jpg Edgar Link pending
vnda-20211231_g3.gif Edgar Link pending
vnda-20211231_g4.jpg Edgar Link pending
vnda-20211231_g5.jpg Edgar Link pending
vnda-20211231_htm.xml Edgar Link completed
vnda-20211231_lab.xml Edgar Link unprocessable
vnda-20211231_pre.xml Edgar Link unprocessable
vnda1231202110-kexhibit42.htm Edgar Link pending
vnda12312021ex10122014path.htm Edgar Link pending
vnda12312021ex10292016path.htm Edgar Link pending
vnda12312021ex231.htm Edgar Link pending
vnda12312021ex311.htm Edgar Link pending
vnda12312021ex312.htm Edgar Link pending
vnda12312021ex321.htm Edgar Link pending